Therefore, we hypothesized high expression of CSE1L and AURK pathway genes may identify p53 WT NSCLC cells most susceptible to mocetinostat or the clinically relevant mocetinostat plus PTX combination. Here, CSE1L is linked to non-small cell lung carcinoma.